에 대한 최신 뉴스 Xilio Therapeutics (NASDAQ:XLO) 주식

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Xilio Therapeutics Inc

The common stock dividend is payable March 14, 2025, to shareholders of record at the close of business on February 26, 2025.

News

Dividends

Avista Boosts Quarterly Dividend From $0.475 To $0.49 Per Share

Editor's Note: This article has been updated to reflect that GSK acquired full rights to CureVac&#8217;s bird flu vaccine candidate.
A Nevada dairy worker has screened positive for the D1.1 strain of bird flu associated with a Louisiana man's death in January, according to a CNN <a href="https://www.cnn.com/2025/02/08/health/bird-flu-variant-nevada-human-case/index.html">report</a>. The Centers for Disease Control and Prevention is working Monday to confirm<a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says"> the initial positive test.</a>
The Details: The Nevada dairy worker who has initially tested positive is currently experiencing mild symptoms, including conjunctivitis or "pink eye," which appears to be a common symptom in recent human infections.&nbsp;
Last week, the U.S. Department of Agriculture said six dairy herds in Nevada<a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says"> tested positive</a> for the D1.1 strain of bird flu, marking the first time the variant of the H5N1 virus was detected in cattle.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a>
The<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> current public health</a> risk remains low, according to the CDC. The agency is using flu surveillance systems to monitor for H5 bird flu activity in people.&nbsp;
In January, President Donald Trump <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">ordered </a>a stop to all communications from CDC. Its website currently displays a banner stating that the site is being "modified to comply with President Trump's Executive Orders."
The CDC resumed publishing its weekly <a href="https://www.cdc.gov/mmwr/index2025.html?ACSTrackingID=USCDC_921-DM144964&amp;ACSTrackingLabel=This%20Week%20in%20MMWR:%20Vol.%2074,%20February%206,%202025&amp;deliveryName=USCDC_921-DM144964">scientific report</a>, the Morbidity and Mortality Weekly Report, last Thursday after being paused for the previous two weeks.&nbsp;
What Else: The H5N1 avian flu continues to spread in wild bird populations as well as in domestic flocks. As many as 15 birds at the Queens and Bronx zoos died last week as a result of the bird flu and a zoo spokesperson<a href="https://gothamist.com/news/bird-flu-suspected-in-deaths-across-multiple-species-at-queens-and-bronx-zoos"> told</a> Gothamist that "vulnerable bird species&#8221; have been moved to protected areas as vets work with city, state and federal regulators.&nbsp;
New York Governor Kathy Hochul has ordered live poultry markets in New York City, Westchester and Long Island to close after several bird flu cases were detected in Queens, Brooklyn and the Bronx last week.&nbsp;
According to the National Emerging Special Pathogens Training &amp; Education Center, more than 60 million poultry have died or<a href="https://netec.org/2023/01/30/situation-report-highly-pathogenic-avian-influenza-ah5n1/"> been culled</a> due to bird flu since the outbreak began in 2022. More than 20 million egg-laying chickens were culled in the last quarter of 2024 alone, creating a large impact on the U.S. poultry industry.&nbsp;
Stocks To Watch: With another human case of bird flu likely having been detected, investors may want to monitor the following stocks that are connected with bird flu vaccines.
Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) in January received an additional $590 million award from the U.S. Department of Health and Human Services to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which acquired full rights to the bird flu vaccine candidate from CureVac BV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) in July 2024, has initiated a Phase I/II study on its development. Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) also has bird flu vaccine candidates in clinical trials.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">Ford Shares Skid After Q4 Report: Details</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

General

CVAC

MRNA

NVAX

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED)

Management

BECN

Beacon Reveals Receipt Of Notice From QXO About Nominations Of Ten Individuals To Stand For Election To Board, Says Nominations Represent Apparent Attempt to Pressure Board To Accept Offer

Guidance

Western Digital Says CEO Designate Irving Tan Shared Go-Forward Strategy At Investor Day 2025; Company Is Now Testing HAMR Technology With Hyperscale Customers

Deutsche Boerse (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBOEY#OTC">DBOEY</a>) reported quarterly earnings of $0.31 per share. This is a 29.17 percent increase over earnings of $0.24 per share from the same period last year. The company reported $1.99 billion in sales this quarter. This is a 6.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

DBOEY

Deutsche Boerse Q4 Adj EPS $0.31 Up From $0.24 YoY, Sales $1.99B Up From $1.86B YoY

Upwork Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) shares are moving higher in Wednesday&#8217;s after-hours session after the company reported strong <a href="https://www.benzinga.com/pressreleases/25/02/g43674755/upwork-reports-fourth-quarter-and-full-year-2024-financial-results">fourth-quarter results</a>.
<ul>
<li>Q4 Revenue: $191.48 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $180.94 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 30 cents, versus estimates of 24 cents</li>
</ul>
Total revenue increased 4% year-over-year. Active clients totaled 832,000 at quarter&#8217;s end. Gross services volume per active client came in at $4,815, up 1% year-over-year. 
Upwork generated $38.6 million in cash from operations and $34.7 million in free cash flow during the quarter. The company ended the period with $305.76 million in cash and cash equivalents. 
&#8220;Our 2024 results are a reflection of our strong execution driving durable, profitable growth, bringing new AI innovations to market, and building long-term shareholder value,&#8221; said Hayden Brown, president and CEO, Upwork. 
&#8220;Upwork&#8217;s superior scale and model means we are poised to continue to gain market share as a trusted source of high-quality talent and work outcomes, powered by AI, in the years ahead.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43676276/robinhood-q4-earnings-highlights-record-revenue-eps-beat-analyst-estimates-crypto-revenue-up-700">Robinhood Q4 Earnings Highlights: Record Revenue, EPS Beat Analyst Estimates, Crypto Revenue Up 700%+</a>
Outlook: Upwork expects first-quarter revenue to be in the range of $186 million to $191 million versus estimates of $183.4 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company anticipates first-quarter adjusted earnings of 24 cents to 26 cents per share versus estimates of 26 cents per share.
Upwork sees full-year 2025 revenue of $740 million to $760 million versus estimates of $758.5 million. The company expects full-year adjusted earnings to be in the range of $1.05 to $1.10 per share versus estimates of $1.18 per share. 
Management is currently discussing the quarter on a conference call that kicked off at 5 p.m. ET.
UPWK Price Action: <a href="http://benzinga.com/quote/upwk">Upwork shares</a> were up 4.9% after hours, trading at $16.30 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

UPWK

Upwork Shares Rise On Strong Q4 Earnings: 'We Are Poised To Continue To Gain Market Share'

HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) reported its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43674614/hubspot-reports-q4-and-full-year-2024-results">details from the report.&nbsp;</a>
The Details:&nbsp;HubSpot&nbsp;reported quarterly earnings of&nbsp;$2.32&nbsp;per share, beating the&nbsp;$2.19 analysts consensus estimate. Quarterly revenue came in at $703.17 million, beating the $673.32 million consensus estimate. 
<ul>
<li>Subscription revenue was $687.3 million, up 21% from the same quarter last year. </li>
<li>Professional services and other revenue was $15.9 million, up 36% year-over-year. </li>
<li>Grew Customers to 247,939 at Dec.31, 2024, up 21% from Dec. 31, 2023.</li>
<li>Average Subscription Revenue Per Customer was $11,312 during the fourth quarter, down 0.5% year-over-year.</li>
<li>Calculated billings were $767.6 million, up 16% on an as-reported basis and 21% in constant currency compared to the prior year&#8217;s quarter.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/25/02/43667841/inflation-is-hot-and-getting-hotter">Inflation Runs Hot In January: &#8216;Houston We Have A Problem,&#8217; Experts Warn</a>&nbsp;
&#8220;We had a solid finish to 2024, highlighting our leadership as a platform company&#8221;, said Yamini Rangan, CEO of HubSpot. 
&#8220;2024 was a transformative year for HubSpot as we reimagined our product, our platform, and company with AI. I&#8217;m excited by the progress we&#8217;ve made in embedding AI across our hubs and the value it&#8217;s driving for customers,&#8221; Rangan added. 
Outlook:&nbsp;HubSpot sees first-quarter revenue of between $697 million and $699 million, versus the $705.71 million estimate, and EPS of between $1.74 and $1.76, versus the $2.00 estimate. 
HubSpot expects fiscal 2025 total revenue in a range of $2.98 billion to $2.99 billion, versus the $2.99 billion estimate, and EPS of between $9.11 and&nbsp;$9.19, versus the $9.14 estimate. 
HUBS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, HubSpot shares are up 5.06% after hours at $823.01 Wednesday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Courtesy of HubSpot, Inc.

Tech

HUBS

HubSpot Shares Climb After Solid Q4 Report: EPS Beat, Revenues Beat

Transocean Reports Total Backlog Of ~$8.3B As Of February 12, 2025

CSCO

Cisco Says Gary Steele, President, Go-To-Market, Notified His Decision To Resign, Effective April 25, 2025, For An External CEO Opportunity - Filing

<a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">Artificial intelligence server</a> company Super Micro Computer, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock has risen over 1,336% in the last five years, backed by demand for AI hardware and infrastructure in line with the AI boom.
Aswath Damodaran, a Professor of Finance at the Stern School of Business at New York University, proclaimed the need for investments in infrastructure to accomplish <a target="_blank" href="https://aswathdamodaran.substack.com/p/ais-winners-losers-and-wannabes-valuing" rel="noreferrer noopener">AI ambitions</a>.
The launch of ChatGPT in 2022 posed a positive catalyst for the server market, as demand for AI servers increased with the generative AI boom.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43442520/strong-iphone-upgrades-ai-features-and-services-growth-fuel-apples-momentum-bofa-analyst-says" rel="noreferrer noopener">Apple May Face Limited Tariff Impact, Trump Administration Could Ease DOJ Pressure: BofA</a>
Dell, Super Micro, and Hewlett Packard are the Big 3 Original Equipment Manufacturers of the AI server market. However, &#8220;Original Design Manufacturer direct&#8221; sales dominate as Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and its Big Tech peers continue to have their servers custom-made, as per <a target="_blank" href="https://www.counterpointresearch.com/insight/post-insight-research-notes-blogs-ai-servers-are-now-one-third-of-the-global-server-market" rel="noreferrer noopener">Counterpoint</a>.
Super Micro&#8217;s <a target="_blank" href="https://ir.supermicro.com/financials/sec-filings/default.aspx" rel="noreferrer noopener">gross margin</a> ranged between 15%-18% in the last three fiscals <a target="_blank" href="https://investors.hpe.com/financial/annual-reports" rel="noreferrer noopener">compared to</a> Hewlett Packard&#8217;s 33.4%-35% and <a target="_blank" href="https://investors.delltechnologies.com/financial-information/sec-filings?field_nir_sec_form_group_target_id=471&amp;field_nir_sec_date_filed_value=&amp;filter_type=&amp;relative_date_range_after=&amp;relative_date_range_before=&amp;exact_date_range_after=&amp;exact_date_range_before=&amp;items_per_page=10" rel="noreferrer noopener">Dell&#8217;s 22%-24%</a> due to the companies&#8217; diversified product portfolio with potentially higher margin segments.
Also, Super Micro priced its AI servers at a discount versus rivals to win market share, Reuters cited CFO David Weigand during a quarterly earnings call.
Super Micro&#8217;s stock value lost 25% in the <a target="_blank" href="https://www.benzinga.com/24/12/42520765/super-micro-drops-below-50-day-average-faces-nasdaq-100-removal-just-months-after-entry" rel="noreferrer noopener">last six months</a> as auditor Ernst &amp; Young quit in October over governance concerns. The company tapped BDO USA as its new auditor.
Super Micro, scrutinized by a Hindenburg Research report and a U.S. Department of Justice probe for alleged accounting fraud, has until February 25 to file its delayed financial reports. The stock lost its position in the Nasdaq 100 index in December 2024, months after joining it in July 2024.
According to the AI server company&#8217;s latest <a target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001375365/b47ec77a-b669-438b-82d3-553ab0d77e45.html" rel="noreferrer noopener">quarterly report</a>, Super Micro&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/10/41355570/super-micro-expands-liquid-cooled-ai-servers-with-nvidia-power" rel="noreferrer noopener">customers include</a> Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), and Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>).
Super Micro remains <a target="_blank" href="https://www.benzinga.com/24/12/42709635/super-micro-and-nvidia-expand-in-taiwan-with-green-energy-and-ai-projects" rel="noreferrer noopener">engaged in constructive endeavors</a>, including collaborating with Taiwan&#8217;s Guo Rui to form a renewable-energy-powered computation center in Taiwan. Reportedly, Nvidia plans to build a secondary headquarters in Taiwan.
Super Micro launched new <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43500503/whats-going-on-with-ai-infrastructure-provider-supermicros-stock-today" rel="noreferrer noopener">AI data center solutions</a> with Nvidia Blackwell, and it has production plants in San Jose, Europe, and Asia.
In January, Super Micro began shipping <a target="_blank" href="https://www.benzinga.com/markets/equities/25/01/42900090/super-micro-begins-shipping-max-performance-servers-with-intel-xeon-6900-series-processors" rel="noreferrer noopener">max-performance servers</a> with Intel Xeon 6900 processors optimized for AI, HPC, and GPU-intensive tasks.
On January 30, Super Micro CEO Charles Liang <a target="_blank" href="https://x.com/charlesliang/status/1885087135922847978" rel="noreferrer noopener">tweeted</a> about expanding its partnership with Elon Musk&#8217;s AI startup,&nbsp;xAI.
On Tuesday, Super Micro reported <a target="_blank" href="https://www.benzinga.com/25/02/43646949/supermicro-sees-conservative-40-billion-revenue-target-despite-auditor-exit-stocks-50-slide" rel="noreferrer noopener">preliminary second-quarter</a> revenue of $5.6 billion—$5.7 billion (below the $5.89 billion consensus), up 54%.&nbsp;
The company cut its fiscal year 2025 guidance to $23.5 billion—$25 billion from its previous forecast of $26 billion—$30 billion (versus the $24.92 billion consensus). It projected fiscal year 2026 revenue of $40 billion versus the $29.92 billion consensus.
The company expects to file&nbsp;its delayed annual and quarterly reports to the U.S. SEC <a target="_blank" href="https://www.benzinga.com/25/02/43651025/smci-climbs-66-in-wednesday-pre-market-whats-going-on" rel="noreferrer noopener">by the deadline</a>.
Analysts rerated the stock upon the results.
<ul>
<li>Wedbush analyst Matt Bryson maintained Super Micro with a Neutral and raised the price target from $24 to $40.</li>
<li>JP Morgan analyst Samik Chatterjee maintained Super Micro with an Underweight and raised the price target from $23 to $35.</li>
<li>Needham analyst Quinn Bolton suspended the rating on Super Micro.</li>
</ul>
Wedbush: Super Micro&#8217;s softer, uninspiring results, the vision of a significantly more robust future, and plans to file its financials before the deadline should reduce uncertainty.
Bryson expects the business to expand considerably in the first half of 2026. However, he is also hesitant to model as aggressively as management forecasts.
JP Morgan: Despite the near-term softness, Super Micro surprised with an updated full-year guide, which implied a strong revenue inflection that the company expects will start a robust AI server revenue cycle.
The price target boost reflects increased conviction from the management team to meet regulatory deadlines.
Needham: Super Micro&#8217;s preliminary revenue and gross margin results fell slightly short of expectations as customers waited to order new Blackwell systems and aggressive pricing on Hopper products.
Bolton maintained his suspended rating as he awaited the filing of the annual and quarterly reports.
Investors can gain exposure to Super Micro through Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>).
Price Action:&nbsp;SMCI stock closed at $39.68 on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43442424/meta-outspends-apple-and-amazon-on-arvr-betting-big-on-future-of-smart-glasses-and-ai" target="_blank" rel="noreferrer noopener">Meta Bets Big on Future of Smart Glasses and AI, Outspends Apple and Amazon on AR/VR</a></li>
</ul>
Image via Shutterstock

Price Target

Reiteration

Analyst Ratings

Trading Ideas

DELL

INTC

MSFT

NVDA

SMCI

SSNLF

Super Micro Rides AI Server Boom, Analysts See Big 2026 Growth Despite Near-Term Challenges

West Fraser Timber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFG#NYSE">WFG</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.06 by 66.67 percent. This is a 105.35 percent increase over losses of $(1.87) per share from the same period last year. The company reported quarterly sales of $1.41 billion which missed the analyst consensus estimate of $1.42 billion by 0.78 percent. This is a 7.20 percent decrease over sales of $1.51 billion the same period last year.

Earnings Beats

Earnings Misses

West Fraser Timber Q4 Adj $0.10 Beats $0.06 Estimate, Sales $1.41B Miss $1.42B Estimate

CORRECTION: Kinross Gold Q4 2024 Adj EPS $0.20 Misses $0.25 Estimate, Sales $1.42B Miss $1.47B Estimate

Sun Life Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLF#NYSE">SLF</a>) reported quarterly earnings of $1.68 per share which missed the analyst consensus estimate of $1.79 by 6.15 percent. This is a 36.59 percent increase over earnings of $1.23 per share from the same period last year.

Sun Life Financial Q4 2024 Adj EPS C$1.68 Misses C$1.79 Estimate

Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) reported its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="http://Fastly Announces Fourth Quarter and Full Year 2024 Financial Results">details from the report. </a>
The Details: The San Francisco-based company reported quarterly losses of 3 cents per share. That&#8217;s down from earnings of 1 cent in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate.
<ul>
<li>Network services revenue was $427.7 million, representing 6% year-over-year growth. </li>
<li>Security revenue was $103 million, representing 11% year-over-year growth. </li>
<li>Other revenue was $12.9 million, representing 61% year-over-year growth.&nbsp;</li>
<li>Enterprise customer count was 596 in the fourth quarter, up 20 from the third quarter of 2024.</li>
<li>Fastly&#8217;s top ten customers accounted for 32% of revenue in the fourth quarter compared to 40% in the fourth quarter of 2023.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/25/02/43667841/inflation-is-hot-and-getting-hotter">Inflation Runs Hot In January: &#8216;Houston We Have A Problem,&#8217; Experts Warn</a>&nbsp;
"We are pleased to report record fourth quarter revenue, exceeding the high-end of our guidance range," said Todd Nightingale, CEO of Fastly.
"Our platform strategy is delivering an accelerated innovation velocity and faster time to value for anyone building web experiences," continued Nightingale. &#8220;We enter 2025 with a strengthened balance sheet, a motivated go-to-market team, and intense focus on efficient customer acquisition and long-term revenue growth."
Outlook:&nbsp;Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate. 
FSLY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Fastly shares are down 18.57% after hours at $8.20 Wednesday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Shutterstock

FSLY

Fastly Shares Tumble After Q4 Report, Weak Forward Guidance

Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $1.01 by 37.62 percent. This is a 77.09 percent decrease over earnings of $2.75 per share from the same period last year. The company reported quarterly sales of $203.97 million which missed the analyst consensus estimate of $222.39 million by 8.28 percent. This is a 39.35 percent decrease over sales of $336.31 million the same period last year.

STNG

Scorpio Tankers Q4 2024 Adj EPS $0.63 Misses $1.01 Estimate, Sales $203.97M Miss $222.39M Estimate

SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.27 by 88.89 percent. This is a 112.5 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $210.31 million which beat the analyst consensus estimate of $202.95 million by 3.63 percent. This is a 6.14 percent increase over sales of $198.14 million the same period last year.

SolarWinds Q4 2024 Adj EPS $0.51 Beats $0.27 Estimate, Sales $210.31M Beat $202.95M Estimate

MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) is looking for Q1 GAAP EPS of $0.35-$0.91 vs $1.07 analyst estimate..

MKSI

MKS Instruments Sees Q1 GAAP EPS $0.35-$0.91 vs $1.07 Est

MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) is looking for Q1 Adj EPS of $1.13-$1.67 vs $1.62 analyst estimate. sees sales of $870.000 million-$950.000 million vs $908.69 million analyst estimate.

MKS Instruments Sees Q1 Adj EPS $1.13-$1.67 vs $1.62 Est; Sees Sales $870.000M-$950.000M vs $908.69M Est

MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $1.95 by 10.26 percent. This is a 83.76 percent increase over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $935.00 million which beat the analyst consensus estimate of $914.18 million by 2.28 percent. This is a 4.70 percent increase over sales of $893.00 million the same period last year.

MKS Instruments Q4 Adj $2.15 Beats $1.95 Estimate, Sales $935.00M Beat $914.18M Estimate

WIIM

Kadant shares are trading lower. The company reported Q4 financial results,

Xilio Therapeutics Inc ( ($XLO) ) has released its Q3 earnings. Here is a breakdown of the information Xilio Therapeutics Inc presented to its inve...

Xilio Therapeutics Reports Q3 2024 Progress and Financials

Xilio Therapeutics reports Q3 results

Morgan Stanley analyst Michael Ulz has maintained their bullish stance on XLO stock, giving a Buy rating yesterday. Michael Ulz has given his Buy r...

Promising Pipeline and Financial Stability Drive Buy Rating for Xilio Therapeutics

Xilio Therapeutics (XLO) announced the appointment of Caroline Hensley as chief legal officer. Hensley most recently served as senior vice presiden...

Xilio Therapeutics appoints Caroline Hensley as CLO

Xilio Therapeutics (XLO) announced plans to present initial data from its ongoing Phase 2 trial for vilastobart, a tumor-activated, Fc-enhanced, hi...

Xilio Therapeutics to present initial Phase 2 data for XTX101 at ASCO GI

Xilio Therapeutics (XLO) announced initial data from its ongoing Phase 2 clinical trial evaluating vilastobart, or XTX101, a tumor-activated, Fc-en...

Xilio reports results from ongoing Phase 2 clinical trial of vilastobart

Xilio Therapeutics ( ($XLO) ) just unveiled an update. On January 21, 2025, Xilio Therapeutics announced initial data from a Phase 2 clinical trial...

Xilio Therapeutics Advances with Phase 2 Trial Data

Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen,...

Xilio Therapeutics announces multiple masked T cell engager programs

AbbVie and Xilio Therapeutics announce collaboration and option agreement

Shares in biotech group Xilio Therapeutics ($XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie Inc. ($ABBV). Xilio Tar...

Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie

ABBV

MCRB

Press Releases

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Small Cap

Opinion

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Contracts

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

AGEN

ALXO

ONCY

RNXT

TSX:ONC

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allakos

BioAtla

BioVie

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

CEL-SCI

Cyclo Therapeutics

Equillium

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

iBio

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Passage Bio

Pluri

Palatin Techs

Rallybio

RenovoRx

Surrozen

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Unity Biotechnology

Exicure

Raymond James

Chardan Capital

Morgan Stanley

Xilio Therapeutics shares are trading higher after the company announced an option-to-license collaboration agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies.

Comments

Xilio Therapeutics

뉴스

에 대한 최신 뉴스 Xilio Therapeutics (NASDAQ:XLO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌